Status:
TERMINATED
Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward
Lead Sponsor:
Federico II University
Conditions:
Diabetes Mellitus
Covid19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
During the current Covid-19 pandemic, many hospitals worldwide have been overwhelmed and strategies based on new technologies have been considered to improve the outcomes in patients with diabetes and...
Detailed Description
Both hyperglycaemia and hypoglycaemia are associated with poor outcomes in patients with COVID-19. In these patients, severe hyperglycaemia after hospital admission is a strong predictor of death amon...
Eligibility Criteria
Inclusion
- All patients admitted at the COVID-19 non-ICU with a diagnosis of Type 2 or Secondary diabetes mellitus (DM) for whom intensive insulin therapy (basal plus at least two boluses) is indicated are eligible for the study.
Exclusion
- Patients on hydroxyurea treatment are excluded (interference with glucose sensor readings).
Key Trial Info
Start Date :
March 19 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04871958
Start Date
March 19 2021
End Date
September 30 2021
Last Update
July 28 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Federico II University Hospital
Naples, Italy, 80131